LAUSR

IL-2 immunotherapy expands tumor-infiltrating DCs through a lymphoid pathway, favoring the conversion of poorly immunogenic into immunogenic tumors. Hidden virtues of interleukin-2 Interleukin-2 (IL-2) is an immunostimulatory cytokine that is being tested as an anticancer therapy due to its ability to activate T cells and natural killer cells. Unexpectedly, Raeber et al. discovered that IL-2 can also activate dendritic cells, an entirely different type of cells involved in antitumor immunity. The authors analyzed data from a clinical trial in human patients being treated with recombinant IL-2. They also pursued more detailed studies in mouse models to identify the mechanisms responsible for dendritic cell activation, helping to explain how IL-2 sensitizes tumors to immune destruction. Tumor-infiltrating dendritic cells (DCs) correlate with effective anticancer immunity and improved responsiveness to anti–PD-1 checkpoint immunotherapy. However, the drivers of DC expansion and intratumoral accumulation are ill-defined. We found that interleukin-2 (IL-2) stimulated DC formation through innate and adaptive lymphoid cells in mice and humans, and this increase in DCs improved anticancer immunity. Administration of IL-2 to humans within a clinical trial and of IL-2 receptor (IL-2R)–biased IL-2 to mice resulted in pronounced expansion of type 1 DCs, including migratory and cross-presenting subsets, and type 2 DCs, although neither DC precursors nor mature DCs had functional IL-2Rs. In mechanistic studies, IL-2 signals stimulated innate lymphoid cells, natural killer cells, and T cells to synthesize the cytokines FLT3L, CSF-2, and TNF. These cytokines redundantly caused DC expansion and activation, which resulted in improved antigen processing and correlated with favorable anticancer responses in mice and patients. Thus, IL-2 immunotherapy–mediated stimulation of DCs contributes to anticancer immunity by rendering tumors more immunogenic.